Homocysteine levels and coronary heart disease in Syria

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 5, Issue 4, 1998, Pages 257-261

  Joubran, Rana ^a   Asmi, Muhamed ^b   Busjahn, Andreas ^c   Vergopoulos, Athanasios ^c   Luft, Friedrich C ^c   Jouma, Muhidien ^d  

^a Department of Clinical Laboratory Medicine ^*

^b Assad University Hospital   (Syrian Arab Republic)

^c HUMBOLDT UNIVERSITY   (Germany)

^d School of Pharmacy

Author keywords

atherosclerosis; cardiovascular risk; coronary heart disease; homocysteine

Indexed keywords

FIBRINOGEN; HOMOCYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYRIAN ARAB REPUBLIC;

ADULT; AGED; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; RISK FACTORS; SYRIA;

EID: 0032431131     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182679800500408     Document Type: Article

References (31)

1. Selhub J, Miller JW. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfation of homocysteine. Am J Clin Nutr 1992; 55: 131–138.
2. McCully KS. Vascular pathology of homocysteinemia: Implication for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111–128.
3. Dalery K, Lussier-Cacan S, Selhum J, Davingnon J, Latour Y, Genest J. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 1995; 75: 1107–1111.
4. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 286: 877–881.
5. Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norving B, Upson B, et al Hyperhomocysteinaemia in stroke: Prevalence, cause and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992; 22: 214–221.
6. Malinow MR, Nieto J, Szklo M, Chambless LE, Bong G. Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. Circulation 1993; 87: 1107–1113.
7. Molgaard J, Malinow MR, Lassvik C, Holm A-C, Upson B, Olsson AG. Hyperhomocysteinemia: An independent risk factor for intermittent claudication. J Intern Med 1992; 231: 273–279.
8. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745–1749.
9. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049–1057.
10. Gartler SM, Hornany SK, Motulsky AG. Effect of chronologic age on induction of cystathionine synthase, uroporphyrinogen 1 synthase, and glucose-G-phosphate dehydrogenase activities in lymphocytes. Proc Natl Acad Sci USA 1981; 78: 1416–1419.
11. Mudd SH, Skovby F, Feby HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al The natural history of homocysteineuria due to cystathionine beta synthase deficiency. Am J Hum Genet 1985; 37: 1–31.
12. Goyette P, Sumner JS, Milos R, Duncan AMV, Rosenblatt DS, Matthews RG, et al Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification. Nature Genet 1994; 7: 195–200.
13. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693–2698.
14. Davidoff F. Blood sugar, disease and nondisease. Ann Intern Med 1997; 127: 235–237.
15. Friedewald WT, Robert IL, Donald SF. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
16. Becker U, Bartl K, Wahlefeld AW. A functional photometric assay for plasma fibrinogen. Thromb Res 1984; 35: 475–484.
17. Fortein LJ, Genest J. Measurement of homocysteine in the prediction of arteriosclerosis. Clin Biochem 1995; 28: 155–162.
18. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescent detection. J Chromatogr 1987; 422: 43–52.
19. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, Van Staden DA, Bissbort S. The prevalence of hyperhomocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991; 69: 527–534.
20. Al Kateb AH, Zarzzour W, Shameah M, Juoma M. Coronary risk factor in angiographically assessed patients from Syria. J Cardiovasc Risk 1998; 5: 31–35.
21. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308–318.
22. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369–6373.
23. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906–1914.
24. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370–1376.
25. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: Results of the 8 year follow-up of healthy men in the Münster Heart Study (PROCAM) Prospective Cardiovascular Münster Study. Isr J Med Sci 1996; 32: 364–370.
26. Pearson TA, LaCava J, Weil HF. Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease. Am J Clin Nutr 1997; 65 (suppl 5):1674S–1682S.
27. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638–644.
28. de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary disease, smoking, and inflammatory markers. Atherosclerosis 1996; 121: 185–191.
29. Bennett JS, Chan C, Vilaire G, Mousa SA, DeGrado WE Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin. J Biol Chem 1997; 272: 8137–8140.
30. Simon Dl, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein llb/llla∗ cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528–535.
31. Wang XL, Wang J, McCredie RM, Wilcken DE. Polymorphisms of factor V, factor VII, and fibrinogen genes: Relevance to the severity of coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 246–251.